ClinicalTrials.gg
Active, not recruitingNCT06628297SVATUpdated Nov 18, 2026

Comparison of Differencens in VO2-max, Perfusion of the Heart and Brain and Cognitive Performance Between Patients With Type 2 Diabetes and Healthy Age Matched Controls.

An observational study in Microvascular Disease, Microvascular Complications and Dementia, sponsored by University Hospital Bispebjerg and Frederiksberg. Active, not recruiting at 1 site in Denmark. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University Hospital Bispebjerg and Frederiksberg · Observational

How we know

Updated Nov 18, 2026Now Active, not recruitingStart date moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
72
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Dementia with a site in Denmark — 6 open to participants now, 12 under way, 1 of them phase 3. Dementia · Denmark.

Started
2025
with 5 others
Observational
9 of 30
3 open now
Primary completion
2027-12
later than 7 of 11 live
Registered
21st of 30
by date
Lead sponsor
3 of 30
University Hospital Bispebjerg and Frederiksberg

Among the 30 studies in Dementia with a site in Denmark, this one is one of 6 that started in 2025, is one of 9 observational ones, reaches primary completion later than 7 of the 11 other live ones, and was the 21st registered.

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

Browse Dementia studies →

Open to participants now

6 of the 30 studies in Dementia with a site in Denmark are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Dementia with a site in Denmark, or all of them as a file.
02

Study summary

In the aging population, ischemic heart disease, stroke and dementia are increasingly prevalent. Diagnosis and treatment of the former two i.e., large-vessel coronary heart disease and endovascular thrombectomy of the brain in relation to stroke have improved significantly. Yet, the majority of elderly patients with ischemic heart disease do not have large-vessel heart disease and it seems that small vessel disease (SVD) may explain a large fraction of these cases as well as the cardiovascular morbidity in the elderly. Hence, the current development in diagnostics and treatments of ischemic heart disease does not address the most common subtype of ischemic disease seen in elderly patients.

It has been suggested that SVD is part of a multisystem disorder and several systematic reviews have addressed the hypothesis of a potential link between small vessel disease of the heart, brain, and kidneys. Cerebral SVD is prevalent in the aging population causing cognitive impairment, dementia, and an increased risk of stroke, and cerebral hypoperfusion is an acknowledged cause of vascular dementia and a possible cause of Alzheimer's disease. Further, cognitive impairment within multiple cognitive domains is highly prevalent in heart failure and is associated to an increased risk of dementia. The link between heart failure and dementia may be due to multisystem SVD, although a direct link between the two is possible.

Among other known risk factors such as age, hypertension, and female sex, diabetes is a major cause of SVD and is linked to coronary heart disease as well as cognitive impairment. The diagnosis of cerebral SVD relies on MRI detecting infarctions, haemorrhages, microbleeds and ischemic white matter changes, i.e. Fazekas score. In contrast, perfusion PET is used to image myocardial perfusion in patients with coronary SVD; and coronary SVD is recognized as a part of the pathophysiology in angina, coronary artery disease, and heart failure. Perfusion PET before and after adenosine-induced vasodilation allows for measuring, the myocardial flow reserve (MFR), i.e. perfusion capacity, which in the absence of regional perfusion defects, is a measure of coronary SVD. Prof. Eva Prescott have recently shown that reduced MFR obtained by 82Rb PET is a strong predictor of future microvascular events and all-cause mortality.

Exercise is well known to improve cognitive health but professor Carl-Johan Boraxbekk has shown that the effect on cognitive performance may be dependent on the initial cerebrovascular status, as patients with moderate to severe white matter changes did not improve after a 6 months physical activation intervention in contrast to patients with mild changes. Yet, it is possible to improve brain function in diabetic patients through either dietary or exercise interventions.

Systemic SVD is measured as cerebral SVD (reduced brain perfusion during acetazolamide-induced vasodilation) and coronary SVD (reduced heart perfusion during adenosine-induced vasodilation). The researchers anticipate that patients with type 2 dabetes have reduced perfusion capacity of the brain and heart correlating to reduced cognition and cardiorespiratory fitness (VO2-max).

Read the detailed description

The goal of this clinical trial is to compare baseline measurements relevant to microvascular disease between patients with diabetes and increased risk of microvascular disease with healthy age-matched control.

The researchers wish to examine if small vessel disease is a disease that affects several organs at once in the same individuals by examining it in the brain and heart in the same participants. The researchers will also test if cardiorespiratory conditioning (VO2-max), blood perfusion to the heart and brain and cognitive performance are correlated in patients with microvascular disease.

To adress these aims the researchers have defined the following assumptions that they will refute or confirm through this study:

  • Patients with type 2 diabetes and increased risk of small vessel disease have significantly reduced perfusion capacity of the brain and heart compared to healthy controls as part of a multisystem disease
  • Perfusion capacity of the brain and heart, the cardiorespiratory fitness level of the subjects and cognitive performance are directly linked.

    48 patients with diabetes and 24 healthy age-matched controls will undergo baseline testing that include:

  • Cardiopulmonal Exercise Test (CPET) to determine cardiopulmonal conditioning (VO2-max)
  • Isometric knee strength (if logistically possible)
  • Echocardiography
  • Blood perfusion capacity of the heart and brain via [15O]H2O-PET scans
  • Brain MRI to determine structural damages
  • Blood samples for basic health check (relevant to inclusion, exclusion and safety) and blood samples looking at endothelial and neurological damage for a biobank
  • Cognitive testing (SCIP-D and CANTAB)

Afterwards the researchers will compare the results between the two groups and see if there is a correlation between VO2-max, blood perfusion to the heart and brain and cognitive performance.

03

Conditions studied

  • Microvascular Disease
  • Microvascular Complications
  • Dementia
  • Diabetes Mellitus Type 2
  • Cerebral Hypoperfusion

Keywords

  • microvascular disease
  • microvascular complications of the heart
  • microvascular complications of the brain
  • diabetes type 2
  • dementia
  • microvascular disease patophysiology
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with type 2 diabetes with increased risk of microvascular disease.

Eligibility criteria

Inclusion Criteria for the patients with type 2 diabetes:

Diabetes type II diagnose with one of the following:

  • Duration over 5 years
  • Moderate microalbuminuria
  • Non-proliferative diabetic retinopathy

    • Speaks and understands Danish (required for reliable cognitive testing)
    • Able to provide informed and written consent

Exclusion Criteria or the patients with type 2 diabetes:

Moderate to high intensity training >1 times/week.

  • Previous AMI, atrial fibrillation, significant cardiac valve disease, HFrEF ( \<45%), asthma.
  • Previous stroke or significant neurological disease including cognitive dysfunction.
  • Ongoing depression.
  • Hypothyroidism
  • Unable or unwilling to participate in training, e.g., due to injury, arthrosis or lung disease.

Inclusion Criteria for the healthy age-matched controls:

  • Age > 60 years
  • No diagnosis of T2D according to WHO\'s criteria.
  • Speaks and understands Danish (required for reliable cognitive testing)
  • Able to provide informed and written consent

Exclusion Criteria for the healthy age-matched controls:

  • Moderate to high intensity training >2 times/week.
  • Previous AMI, atrial fibrillation, significant cardiac valve disease, HFrEF (LVEF \<45%), asthma.
  • Previous stroke or significant neurological disease including cognitive dysfunction.
  • Ongoing depression.
  • Hypothyroidism
  • Unable or unwilling to participate in training, e.g., due to injury, arthrosis or lung disease.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
72 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • 48 patients with type 2 diabetes and increased risk of microvascular disease

    Baseline measurements of: * \[15O\]H2O PET of heart and brain * Blood sampling * Echocardiography * Brain MRI * Cognitive tests * Cardiorespiratory fitness test * Muscular function test

    Diagnostic Test: PET

  • 24 healthy age-matched participants

    Baseline measurements of: * \[15O\]H2O PET of heart and brain * Blood sampling * Echocardiography * Brain MRI * Cognitive tests * Cardiorespiratory fitness test * Muscular function test

    Diagnostic Test: PET

Interventions

  • Diagnostic testPET

    PET imaging will be performed with a Discovery 710 PET/CT scanner (GE Healthcare, Milwaukee, WI, USA). Four 5-minute PET recordings will be performed of each subject within a single scanning session of 70 min. Two consecutive 5-minute scans are conducted of the heart and brain in rest. \[15O\]H2O, is produced on-site (GENtrace, GE, Uppsala, Sweden), and 600 MBq \[15O\]H2O is intravenously injected by an automatic Hidex Radiowater Generator (Hidex, Turku, Finland). To induce heart vasodilation, adenosine is infused (140 g/kg/min) for 6 min and a scan of the heart is repeated. To induce brain vasodilation, 1 g of acetazolamide is infused over 5 min and 15 min later the brain is scanned. Myocardial perfusion is calculated using CarimasCE software version 1.3.1. (Turku, Finland). Cerebral perfusion is calculated using PMOD software (PMOD Technologies, Switzerland).

    Also known as: MRI, VO2-max, cognitive testing

06

What researchers measure

Primary outcomes

  1. [15O]H2O PET assessment of the blood perfusion to the brain

    We will use the scan to determine our primary outcome: Blood perfusion to the brain. Radioactive water (\[15O\]H2O) will be used as a PET-tracer since it follows the blood and is the gold standard tracer for PET-based blood perfusion measurements. We measure the blood perfusion of both the brain as the perfusion capacity, meaning the difference between blood perfusion to the organ at rest and the maximally possible perfusion. In the brain we use injection of diamox to stimualte maximal dilation of the cerebral arteries which corresponds to the maximally possible perfusion of the brain.

    Time frame: From baseline testing to end of study, 6 months

  2. [15O]H2O PET assessment of the blood perfusion of the heart

    We will use the scan to determine our primary outcome: Blood perfusion to the heart. Radioactive water (\[15O\]H2O) will be used as a PET-tracer since it follows the blood and is the gold standard tracer for PET-based blood perfusion measurements. We measure the blood perfusion of both the heart as the perfusion capacity, meaning the difference between blood perfusion to the organ at rest and the maximally possible perfusion. In the heart we use injection of adenosin to stimualte maximal dilation of the coronary arteries which corresponds to the maximally possible perfusion of the heart.

    Time frame: From baseline testing to end of study, 6 months

Secondary outcomes

  1. Cognitive performance (CANTAB)

    Testing of a broad range of cognitive functions. The test is tablet based and one of the most \&#34;investigator-independent\&#34; cognitive tests available. The test takes around 45 minutes to perform.

    Time frame: From baseline testing to end of study, 6 months

  2. Cognitive Performance (SCIP-D)

    Assessed via SCIP-D in order to evaluate a broad range of cognitive areas in around 15-20 minutes. Both groups will undergo both tests. The primary investigator will receive learning in how to carry out the SCIP-D correctly. SCIP-D is a more clinically relevant test that can be used in a clinical setting to identify patients with cognitive dysfunction.

    Time frame: From baseline testing to end of study, 6 months

  3. Cardiorespiratory fitness (VO2-max)

    Will be assessed as the maximal or peak oxygen consumption (VO2-max or VO2-peak) during a cardiopulmonal exercise test (CPET).

    Time frame: From baseline testing to end of study, 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Have not gotten the necessary clearence

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2025 (actual). Primary completion is estimated for Dec 2027, 29 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Nov 2024 → Jul 2025 and primary completion Jan 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2024
First posted
Oct 4, 2024
StartActual
Jul 1, 2025was Nov 2024
Primary completionEst.
Dec 2, 2027was Jan 2027
CompletionEst.
Dec 2, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Active, not recruiting
changed Nov 18, 2026
Start date
Nov 2024→Jul 1, 2025 (actual)
Nov 18, 2026
Primary completion
Jan 2027→Dec 2, 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Not yet recruiting→Active, not recruiting
    Start date Nov 2024→Jul 1, 2025 (now actual)
    Primary completion Jan 2027→Dec 2, 2027
    + 4 other changes: identifiers, verification date, oversight details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06628297
Lead sponsor
University Hospital Bispebjerg and Frederiksberg
Collaborators
Danish Cardiovascular Academy, Bispebjerg Hospital, The Dagmar Marshall Foundation, Steno Diabetes Center Copenhagen
Responsible party
Thomas Ehlig Hjermind Justesen (Principal Investigator, University Hospital Bispebjerg and Frederiksberg) — Principal investigator
First posted
Oct 4, 2024
Start date
Jul 1, 2025
Primary completion
Dec 2, 2027 (estimated)
Completion
Dec 2, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Thomas EHJ Primary Investigator, Medical Doctor
principal investigator · University Hospital Bispebjerg and Frederiksberg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion